Latest filings (excl ownership)
ARS
2023 FY
Annual report to shareholders
26 Apr 24
DEFA14A
Additional proxy soliciting materials
26 Apr 24
DEF 14A
Definitive proxy
26 Apr 24
S-8
Registration of securities for employees
14 Mar 24
10-K
2023 FY
Annual report
14 Mar 24
8-K
Monte Rosa Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
14 Mar 24
8-K
Monte Rosa Therapeutics Provides Corporate Update and Key Anticipated Milestones for 2024
8 Jan 24
10-Q
2023 Q3
Quarterly report
9 Nov 23
8-K
Monte Rosa Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update
9 Nov 23
8-K
Monte Rosa Therapeutics Announces $25 Million Registered Direct Offering, Priced At- the-Market Under Nasdaq Rules
26 Oct 23
424B5
Prospectus supplement for primary offering
26 Oct 23
8-K
Monte Rosa to receive an upfront payment of $50 million and potential future payments exceeding $2 billion
17 Oct 23
10-Q
2023 Q2
Quarterly report
10 Aug 23
8-K
Monte Rosa Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update
10 Aug 23
8-K
Departure of Directors or Certain Officers
26 Jul 23
8-K
Amendments to Articles of Incorporation or Bylaws
14 Jun 23
10-Q
2023 Q1
Quarterly report
11 May 23
8-K
Monte Rosa Therapeutics Announces First Quarter 2023 Financial Results and Provides Corporate Update
11 May 23
ARS
2022 FY
Annual report to shareholders
26 Apr 23
DEFA14A
Additional proxy soliciting materials
26 Apr 23
DEF 14A
Definitive proxy
26 Apr 23
PRE 14A
Preliminary proxy
12 Apr 23
8-K
Departure of Directors or Certain Officers
23 Mar 23
S-8
Registration of securities for employees
16 Mar 23
10-K
2022 FY
Annual report
16 Mar 23
8-K
Monte Rosa Therapeutics Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
16 Mar 23
8-K
From Serendipity to Rational Design Taking Molecular Glue Degraders to New Heights | January 2023
9 Jan 23
8-K
Monte Rosa Therapeutics Reports Third Quarter 2022 Financial Results and Business Updates
10 Nov 22
10-Q
2022 Q3
Quarterly report
10 Nov 22
8-K
Regulation FD Disclosure
24 Oct 22
10-Q
2022 Q2
Quarterly report
11 Aug 22
8-K
Monte Rosa Therapeutics Reports Second Quarter 2022 Financial Results and Business Updates
11 Aug 22
EFFECT
Notice of effectiveness
14 Jul 22
CORRESP
Correspondence with SEC
11 Jul 22
UPLOAD
Letter from SEC
8 Jul 22
S-3
Shelf registration
1 Jul 22
8-K
Submission of Matters to a Vote of Security Holders
15 Jun 22
DEFA14A
Additional proxy soliciting materials
8 Jun 22
10-Q
2022 Q1
Quarterly report
11 May 22
8-K
Monte Rosa Therapeutics Reports First Quarter 2022 Financial Results and Business Updates
11 May 22
Latest ownership filings
144
Notice of proposed sale of securities
10 Apr 24
SC 13G/A
PRICE T ROWE ASSOCIATES INC /MD/
10 Apr 24
SC 13G
BAKER BROS. ADVISORS LP
14 Feb 24
SC 13G/A
Cormorant Asset Management, LP
14 Feb 24
SC 13G/A
BlackRock Inc.
14 Feb 24
SC 13G/A
PRICE T ROWE ASSOCIATES INC /MD/
14 Feb 24
SC 13G/A
Avoro Capital Advisors LLC
14 Feb 24
SC 13G/A
FMR LLC
9 Feb 24
4
Markus Warmuth
4 Jan 24
4
Owen B. Wallace
4 Jan 24
4
Jullian G Jones
4 Jan 24
4
Filip Janku
4 Jan 24
4
Philip Nickson
4 Jan 24
4
Edmund Dunn
4 Jan 24
SC 13D/A
Versant Venture Capital VI, L.P.
9 Nov 23
3
Edmund Dunn
18 Aug 23
144
Notice of proposed sale of securities
15 Aug 23
4
Anthony M. Manning
26 Jul 23
3
Anthony M. Manning
26 Jul 23
4
Ali Behbahani
15 Jun 23
4
Jan Skvarka
15 Jun 23
4
Christine Siu
15 Jun 23
4
ANDREW N SCHIFF
15 Jun 23
4
Alexander Mayweg
15 Jun 23
4
Kimberly Blackwell
15 Jun 23
4
Jan Skvarka
31 Mar 23
3
Jan Skvarka
24 Mar 23
SC 13G/A
Cormorant Asset Management, LP
14 Feb 23
SC 13G/A
PRICE T ROWE ASSOCIATES INC /MD/
14 Feb 23
SC 13G/A
Avoro Capital Advisors LLC
14 Feb 23
SC 13G/A
FMR LLC
9 Feb 23
SC 13G
BlackRock Inc.
3 Feb 23
4
Owen B. Wallace
4 Jan 23
4
Markus Warmuth
4 Jan 23
4
Philip Nickson
4 Jan 23
4
Sharon Townson
4 Jan 23
4
Jullian G Jones
4 Jan 23
4
John C. Castle
4 Jan 23
4
Ajim Tamboli
4 Jan 23
4
Filip Janku
4 Jan 23